Research
Hormonal
GLP-1 receptor agonists protect endothelial function by reducing oxidative stress, inhibiting inflammation, and promoting nitric oxide (NO) production.
This node explains the biological mechanism: GLP-1 drugs help keep blood vessel linings healthy by reducing inflammation and oxidative stress, which prevents the buildup of plaque. This is a key reason why these drugs protect the heart.
ModerateSupportsMEDIUM confidence
GLP-1RAs protect endothelial cell function through various mechanisms... liraglutide activates AMP-activated protein kinase (AMPK) and PI3K/ Akt pathways... enhancing NO production (80)... GLP-1RAs also decrease the expression of adhesion molecules ICAM and VCAM in endothelial cell, inhibiting NF-kB phosphorylation (92).
Why this rating
The evidence is largely from basic and preclinical studies (cell cultures, animal models) as described in the review, with some clinical correlation.
Source
Anti-atherosclerotic effect of incretin receptor agonists
Xin Wang et al. · Frontiers in Endocrinology · 2024
DOI 10.3389/fendo.2024.1463547
narrative_reviewCited 9×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Incretin receptor agonists (IRAs), including GLP-1RAs and dual GIP/GLP-1RAs, reduce the risk of major adverse cardiovascular events (MACE) and improve lipid profiles and blood pressure in patients with type 2 diabetes.Good
- GLP-1 receptor agonists reduce foam cell formation and promote anti-inflammatory M2 macrophage polarization, thereby stabilizing atherosclerotic plaques.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →